SCHEMBL21554085

SCHEMBL21554085

O=C(NC1CC1)c1c(Cl)nc(Cl)nc1NC1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.40
ADORA3 P0DMS8 2/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
FLT3 P36888 5/20 0.37
TYRO3 Q06418 5/20 0.37
MERTK Q12866 5/20 0.37
GAS6 Q14393 5/20 0.37
TP53 P04637 1/20 0.36
MDM2 Q00987 1/20 0.36
ADRA2A P08913 2/20 0.36
HRH1 P35367 2/20 0.36
HTR2B P41595 2/20 0.36
MCHR1 Q99705 2/20 0.36
TAS1R3 Q7RTX0 2/20 0.36
TAS1R1 Q7RTX1 2/20 0.36
TAS1R2 Q8TE23 2/20 0.36
P2RX7 Q99572 1/20 0.36
HPGD P15428 1/20 0.36
SYK P43405 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23371374 0.78 NPY5R (0.37) ADORA3ADORA2AADORA1HTR2BKMT2A
SCHEMBL21554056 0.73 TYRO3 (0.54) FLT3TYRO3MERTKGAS6SYK
SCHEMBL20873902 0.68 PPARG (0.37) POLB
SCHEMBL1609288 0.68 NPSR1 (0.40) ADORA3ADORA2AADORA1KMT2A
SCHEMBL17625052 0.66 KMT2A (0.36) ADORA3ADORA2AADORA1KMT2A
SCHEMBL13165484 0.66 PDE10A (0.36) ADORA3ADORA2AADORA1AXLKMT2A
SCHEMBL19822682 0.66 KMT2A (0.36) ADORA3ADORA2AADORA1AXLKMT2A
SCHEMBL13184884 0.66 PDE4A (0.41) ADORA3ADORA2AADORA1AXLKMT2A
SCHEMBL20609719 0.66 TYRO3 (0.64) FLT3TYRO3MERTKGAS6AXL
SCHEMBL16321938 0.65 CYP2C9 (0.38) ADORA3ADORA2AADORA1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851087-B2 Synthesis of cerdulatinib PORTOLA PHARMACEUTICALS, INC. (US) 2020-12-01 US disclosed
US-20190337930-A1 SYNTHESIS OF CERDULATINIB ALEXION PHARMACEUTICALS, INC. 2019-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337930-A1 SYNTHESIS OF CERDULATINIB JAK2, DCK, CERS2 POLB 843/4885ADORA3 3369/4885ADORA2A 3783/4885
US-10851087-B2 Synthesis of cerdulatinib JAK2, DCK, CERS2 POLB 843/4885ADORA3 3369/4885ADORA2A 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.